EMEA-002370-PIP03-22 - paediatric investigation plan
pemigatinib
PIPHuman
Polish is available via eTranslation, the European Commission's machine translation service.
Translate to Polish | Important information about machine translation
Key facts
- Invented name
- Pemazyre
- Active substance
- pemigatinib
- Therapeutic area
- Oncology
- Decision number
- P/0472/2022
- PIP number
- EMEA-002370-PIP03-22
- Condition(s) / indication(s)
- Treatment of myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement
- Route(s) of administration
- Oral use
- Contact for public enquiries
Incyte Biosciences Distribution B.V.
E-mail: RA@incyte.com
- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Nie